Equivac® 2in 1

Description:

• Equivac 2 in 1 is used in the prevention of tetanus due to Clostridium tetani and in the control of strangles due to Streptococcus equi subspecies equi in horses.
• Equivac 2 in 1 is one of a range of Equivac products available for tetanus and strangles treatment and control.

Pack sizes:

• 20 x 1 mL syringes.

SDS

• Equivac 2 in 1 provides a more practical and economical means of vaccinating simultaneously for both tetanus and strangles than purchasing and administering two separate vaccines.
• Prevention of tetanus: A single dose of Equivac 2 in 1 given to an unimmunised horse at the time of wounding or surgery may not prevent tetanus. For short-term prevention of tetanus, Equivac® TAT should also be used. See entry for Equivac TAT.
• Combined Active-Passive Protection: Equivac 2 in 1 can be administered simultaneously with Equivac TAT. A separate needle and syringe should be used for each product and administration should be on opposite sides of the body. If initiating a primary course the second dose of Equivac 2 in 1 should be administered 3 to 6 weeks later.
• Zoetis offers a guarantee against tetanus infection if horses are vaccinated by veterinarians with Equivac 2 in 1 in accordance with the guidelines of the Equine Infectious Diseases Advisory Board and the dose is registered with the health4horses.com.au product registry.

Dosage:

• See product leaflet for full instructions.
• 1 mL injected intra-muscularly.
• For primary immunisation of horses against strangles, horses 3 months of age or older should be given 3 doses of vaccine at intervals no less than 2 weeks apart. For ongoing immunisation, booster doses should be given annually, or every 6 months for horses at higher risk of exposure. Equivac® S may be used for strangles vaccination where tetanus inclusion is not warranted.
• For primary immunisation of horses against tetanus, horses 3 months of age and older should be given 2 doses at intervals of 4 to 6 weeks, followed by a booster 12 months later. Further boosters for tetanus are recommended by the Equine Infectious Diseases Advisory Board every 12 months for maximal protection against tetanus infection.
• The product leaflet should be consulted for guidance as to the use of strangles vaccine in the event of an outbreak.
• It is recommended that strangles vaccination be a component of a herd-health biosecurity-focussed management program for the prevention and control of strangles in horses.

Storage:

  Store between 2°C and 8°C. (Refrigerate. Do not freeze). Protect from light

Human Safety

Additional user safety

Take care to avoid accidental self-injection. In the event of self- administration, seek medical attention if you are concerned and show the package leaflet or the label, to the Medical Practitioner.

First Aid Statement

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Registered label warnings

Withholding Periods

Zero (0) days

ESI

ESI not applicable

Side Effects

Localised swelling may occasionally develop at the site of injection. On rare occasions systemic signs have been observed following vaccination against strangles. This appears to occur when horses have been sensitized to Streptococcus equi by exposure to infection or when they are incubating the disease. Horses which show an abnormally severe reaction following vaccination should not receive further doses of vaccine containing a strangles component for twelve months. Tetanus immunisation should be completed with Equivac T. Local reactions are more evident if the vaccine is injected subcutaneously. Provided the injection has been carried out aseptically, any swelling which occurs at the site of inoculation should resolve spontaneously.